Published on: 04/25/17A large controlled clinical study was conducted on CBD for patients with Lennox-Gastaut syndrome (LGS). The results will be presented at the 69th Annual Meeting of the American Academy of Neurology April 22 to 28, 2017 in Boston. As a sneak preview, we can disclose a finding that CBD reduces epileptic seizures by half for many patients.
Science Daily reported on the latest findings of research into cannabidiol and refractory epilepsy. Ordinary drugs couldn’t prevent or reduce seizures for these patients.
CBD reduces epileptic seizures by half
The study found that seizures were reduced by at least half in children and adults with LGS. Best of all, CBD isn’t psychoactive, so there are no ethical concerns about giving it to kids.
Author of the randomized, double-blind, placebo-controlled study, Anup Patel, member of the American Academy of Neurology, and MD of the National Children’s Hospital, as well as State University College of Medicine in Columbus said the study showed that cannabidiol holds “great promise.”
A selection of our products
Reduction of drop seizures urgent
225 People living with LGS with an average age of 16 were monitored for 14 weeks during the trial. LGS is usually diagnosed in early childhood and patients experience multiple seizures including drop seizures. This kind of seizure causes loss of consciousness and convulsions.
Drop seizures can’t be treated with medication and can be very dangerous. Patients with LGS often suffer intellectual impairment because of brain damage caused by these seizures.
These frightening seizures might be brief, but often lead to injury and land patients in the emergency rooms of hospitals. Reducing drop seizure frequency is therefore a priority.
Study verifies dosage
Those participating in the study experienced an average of 85 drop seizure a month. Typically, these patients have tried six different epilepsy drugs with no success, and were still taking three during the study. There were three groups. One was given 20 mg/kg cannabidiol daily, another 10 mg/kg, and the placebo group received no CBD.
Participants who were give the 20mg experienced a 42% reduction in drop seizures. These participants found that they had at least half as many seizures. Patients given 10mg experienced a 37% reduction in drop seizures. 17% of the placebo group reported fewer seizures. This is full confirmation that CBD reduces seizures for many even when other drugs don’t work.
Side effects well tolerated
94% of the participants using 20mg of CBD reported loss of appetite and sleepiness, but the effect was moderate to mild. Researchers concluded that CBD is well tolerated. On the lower dose, 84% reported the same side effects. 72% of the placebo group also said they felt sleepy and had less appetite.
Plan for New Drug Application
Patel said cannabidiol might be an important new option for treating LGS patients. The researches plan to submit a New Drug Application to the Food and Drug Administration later this year.
It’s ironic that CBD should be considered a “new drug” since people have been reporting that CBD reduces seizures for years. However, the new research vindicates those who have moved mountains to get CBD for refractory epilepsy. Many of these people have said that CBD reduces epileptic seizures dramatically, and some say it eliminates them almost completely.
Disclaimer: Views expressed here do not necessarily reflect those of Endoca and its staff. This article is not intended to provide medical advice, diagnosis, treatment or cure. Endoca CBD products have not been approved by the US Food and Drug Administration (FDA).